This is what the next frontier in diabetes management looks like:

FreeStyle Libre system has been described as our ultimate wearable. It's a CGM that comes calibrated and doesn't require fingersticks.² With the FreeStyle LibreLink app, you can capture real-time glucose levels, eight-hour history and see how your glucose levels are changing throughout the day.

Combine that with Novo Nordisk's latest connected pens that give users accurate dosages and an injection history that includes size and time of your last dose, keeping your last 800 doses.

Given the large and growing base of FreeStyle Libre users, this partnership between Abbott and Novo Nordisk has the potential to significantly improve diabetes management, giving users the ability to be better informed and personalize their care with technology at their fingertips.

"It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "Diabetes is a time intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake.

"By enabling insulin dosing data from Novo Nordisk's connected pens to be shared with our digital health tools, we’ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life."

How soon will our devices work together to better help you manage your diabetes? We're working as quickly as possible. It's an exciting development and we wanted to share with you what's on the horizon with our smart technology.

For more about Novo Nordisk, please visit novonordisk.com

*This integrated solution is not available in the United States.